SPPL2A

Across TCGA pan-cancer cohorts, SPPL2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPPL2A data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPPL2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPPL2A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, HNSC, and COAD are the cancer types where SPPL2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	20	view →
HNSC	DFS	Quartile	All	0.220	0.860	.014	13	view →
COAD	DFS	Quartile	III,IV	0.726	1.000	.043	6	view →
LUAD	DFS	Median	All	0.887	1.000	.018	3	view →
PDAC	OS	Tertile	IV	0.472	0.962	.024	3	view →
LSCC	DFS	Quartile	III,IV	1.000	0.619	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPPL2A–CCRCC (OS)

Open the CCRCC breakdown →